Astragaloside IV protects against the pathological cardiac hypertrophy in mice
Authors:
- 1 January 2018
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 97, 1468-1478
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- The annual global economic burden of heart failureInternational Journal of Cardiology, 2014
- Astragaloside IV attenuates glycated albumin-induced epithelial-to-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cellsCell Stress and Chaperones, 2014
- Toll‐Like Receptor‐2 Mediates Adaptive Cardiac Hypertrophy in Response to Pressure Overload Through Interleukin‐1β Upregulation via Nuclear Factor κB ActivationJournal of the American Heart Association, 2013
- Vitexin protects against cardiac hypertrophy via inhibiting calcineurin and CaMKII signaling pathwaysNaunyn-Schmiedeberg's Archives of Pharmacology, 2013
- Negative regulation of TBK1‐mediated antiviral immunityFEBS Letters, 2013
- PAMPs and DAMPs: signal 0s that spur autophagy and immunityImmunological Reviews, 2012
- Cardiac-specific mindin overexpression attenuates cardiac hypertrophy via blocking AKT/GSK3β and TGF-β1–Smad signallingCardiovascular Research, 2011
- IκB kinase ε and TANK-binding kinase 1 activate AKT by direct phosphorylationProceedings of the National Academy of Sciences, 2011
- Innate immune signaling in cardiac ischemiaNature Reviews Cardiology, 2011
- Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancerJournal of Molecular Signaling, 2010